Abbreviations: TBD Additional File #1: Raw Dataset Additional File#2: Supplementary Methods Total words w/ abstract (total allowed 5000): 4363 Total words w/o abstract: 4014 Abstract (total allowed 350): 350 References (total allowed 50): 38 Abstract 1
were found in the EGFR expressing cluster. EGFR expression in the subset of drug-treated lines 24 was statistically significant (p<.05). The EGFR expressing cluster was of lower tumor initiating 25 potential in comparison to the AKT/TORC1 activated cluster. Though not statistically significant, 26 EGFR expression trended with improved patient prognosis while AKT/TORC1 activated samples 27 trended with poorer outcomes. 28
Conclusions: Quantitative single cell heterogeneity profiling resolves signaling diversity into 29 meaningful non-obvious phenotypic groups suggesting EGFR is decoupled from AKT/TORC1 30 signalling while identifying potentially valuable targets for personalized therapeutic approaches 31 for deadly tumor-initiating cell populations. 32
33
Introduction 34 35
The cell of origin for many cancers is a specific, rare subset of cancer cells responsible for 36 tumor initiation, cellular heterogeneity and various features that underlie the malignant nature of 37 the cancer types which they have been identified in. (1,2) Among those cancers with a cancer 38 stem cell origin is the highly malignant and deadly glioblastoma brain tumor. Patients have a 39 median survival of 14.6 months from diagnosis and five year survival is an abysmal 5%. (3) 40 Patient glioblastoma tumors yield relatively stable cancer stem-like, tumor initiating cell 41 populations which retain some of the phenotypical and genetic heterogeneity of the cancers they 42 produce in vitro. (4) Being able to recover these cells from patient biopsies in vitro are a robust 43 predictor of clinical progression and outcome. These cells additionally serve as useful substrates 44 for drug discovery and to determine the essential molecular signaling landscape contributing to in 45 vivo malignancy and resistance. (5,6) 46 The mechanisms underlying gliomasphere malignancy can be defined by pathway 47 redundancies in the biological systems controlling states of oncogenic activation in cancer cells 48 and their cancer initiating subtypes. (4, 5) Signaling along the EGFR-PTEN-AKT-TORC1 49 signaling axes provide phenotypic features in gliomasphere cell populations. (7) These pathways 50 are especially important in governing cellular fate decisions by transmitting signals controlling 51 survival, self-renewal, growth, proliferation, metabolism, glycolytic adaptation, drug efflux and 52 symmetric division, among other essential features. (8) (9) (10) (11) Targets of EGFR signaling 53 have long been the therapeutic and diagnostic targets of glioblastoma which extends into the era 54 of cancer immunotherapy, which utilizes EGFR in chimeric antigen receptor (CAR) T-cell therapy. 55 (12,13) 56 Clustering gliomasphere models according to The Cancer Genome Atlas (TCGA) 57 classification system has provided insight into the genetic landscape of gliomaspheres. (10) 58
Mesenchymal and non-mesenchymal gliomasphere subtypes have been delineated with non-59 mesenchymal gliomaspheres consisting of both classical and proneural subtypes. (11) Other 60 studies have found gliomasphere models cluster according to a lower malignancy proneural and 61 higher malignancy mesenchymal classification with proneural status conferring phenotypes with 62 lower sphere formation and improved survival in in vivo xenografts of gliomaspheres. (14,15) 63 Based on the gene-level mutations, EGFR mutations (including point mutations, 64 amplifications, rearrangements, and alternative splicing) are found in all subtypes of glioblastoma 65 and are present in 57% of glioblastoma (7, 16, 17) . At the protein level, cellular EGFR expression 66 is tightly controlled in normal but not in cancerous cells by epigenetic regulation and protein 67 degradation pathways, leading to overall high EGFR protein levels (18, 19) . These findings indicate 68 that the gene-level mutations of EGFR and its protein-level expression can be vastly different. 69
Given the discrepancies between the gene-level mutations and the protein-level expression 70 of EGFR and other molecules in the EGFR signaling pathways, it is important to detect the protein 71 level changes in gliomasphere. Multiparameter single cell measurement of EGFR, PTEN, 72 activated AKT and TORC1 signaling had been used previously to aggregate and identify 73 prognostic glioblastoma subtypes. (20) By extending this methodology across a panel of patient-74 derived gliomasphere samples, we sought to observe and detail the signaling diversity within this 75 stem-like subset of cells. In measuring this native signaling heterogeneity and deploying cluster-76 based analyses with comparison to genotypic and phenotypic descriptors, features of response and 77 target characterization can be observed. 78
79
Results 80
Experimental design 81
Patient glioblastoma tumors (Fig. 1A, left ) were dissociated and placed in defined serum 82 free enrichment media to select for in vitro growth and expansion of gliomaspheres as 83 neurospheres (Fig. 1A, middle, right) . After stem-like cell selection and enrichment, neurospheres 84 are dissociated into single cells and loaded into chambers of microfluidic cell array chips for 85 quantitative immunocytochemical staining and imaging ( Fig. 1B, left, Supplementary Methods) . 86
Imaging software quantifies the average fluorescent intensity from each cell for each defined 87 biomarker as the means to reflect individual cellular protein concentration (Fig. 1B, middle) . 88
Bioinformatic analysis of a dataset of all cells from a series of samples resolves complex intra-89
and -inter sample signaling heterogeneity. The resulting data is validated with genotypic and 90 phenotypic measures to assess functional status (Fig. 1C, bottom correlation coefficients between PTEN and pS6 and pAKT and pS6 ( Fig. 2A) . Boxplots of single 99 cell expression of these markers for each sample revealed unique sample diversity and substantial 100 molecular and cellular heterogeneity ( Fig. 2B ). Boxplots of all cells showed the spread of values 101 for each marker in the dataset, showing, while individual parameters were not skewed, there 102 existed a wide distribution of values for each marker (Fig. 2B ). Self-organizing maps (SOMs) 103 resolved forty-nine unique molecular phenotypes across patients (Fig. 2C ). Unsupervised 104 hierarchical clustering based on neighborhood frequency vectors (NFVs) of self-organizing map 105 (SOM) projections in Fig. 2C yielded two predominant clusters ( Fig. 3B-3C) . By taking the 106 average biomarker intensity of all cells in each cluster, two quantitative multiparameter signaling 107 phenotypes emerged (Fig. 3C, Supplemental Methods) . 108
Identified clusters revealed Cluster I to becharacterized by significantly high EGFR 109 expression (p = 0.0003) with decreased pAKT and TORC1 in comparison to Cluster II, which had 110 lower EGFR expression and higher pAKT and pS6 levels (p = 0.08, and p = 0.09 respectively). 111 PTEN expression was statistically insignificant and barely discernible between clusters. 112
113

TCGA grouping of gliomaspheres reveal genotypic heterogeneity in clusters 114
The Cancer Genome Atlas (TCGA) subgroupings were available on twelve of fifteen 115 gliomasphere samples across the EGFR expressing Cluster I (5/7 samples, 71.4%) and 116 AKTAKT/TORC1 activated Cluster II (7/8 samples, 87.5%) (Fig. 3A) . The EGFR expressing 117
Cluster I had two proneural samples (2/5, 40.0%), two classical samples (2/5, 40.0%) and one 118 mesenchymal sample (1/5, 20.0%). Isocitrate dehydrogenase 1 gene mutations (IDHR1324) were 119 found in both proneural samples in this cluster (patients 2 and 3). (21) Within the 120 AKTAKT/TORC1 activated Cluster II, there were three classical samples (3/7, 42.8%), three 121 proneural samples (3/7, 42.8%) and one mesenchymal sample (1/7, 14.2%) (Supplemental Table  122 2). 123
124
High EGFR expressing Cluster I samples are responsive to EGFR inhibition 125 Visualization of single cell EGFR expression profiling revealed a broad diversity in EGFR 126 expression ( Fig. 3A) . A randomly selected subsample of seven gliomasphere lines, all of which 127 were either proneural or classical samples, were tested for response to the EGFR blocker erlotinib 128 ( Fig. 3B ). LC50 measurements of sphere size and sphere number showed EGFR expression Cluster 129 I had lower LC50 and high AKTAKT/TORC1 Cluster II had higher LC50s (Sphere size: Cluster I 130 LC50 mean = 0.26µM, Cluster II LC50 mean = 3.27µΜ. Sphere number: Cluster I LC50 mean = 131 0.33µM, Cluster II LC50 mean = 5.22µM). Non-parametric Mann-Whitney U tests on LC50s of 132 sphere size and sphere number showed significant response to EGFR blockade in EGFR 133 expressing Cluster I in comparison to AKTAKT/TORC1 activated Cluster II (Sphere size, p = 134 0.029, SD = 3.57, two-tailed; Sphere number p = 0.029, SD = 5.81). Though significant differences 135 in sphere size and sphere number were found, the large standard deviation prohibits definitive 136 discrimination between clusters. Significant differences were found in mean EGFR expression 137 and borderline significance in median EGFR expression within this subsample of drug-treated 138 lines, indicating a relationship between receptor expression and drug response (p =0.0418 mean, 139 0.0501 median, T test, unpaired, 2-sided, unequal variance) (Supplemental Information). 140
141
Molecularly defined clusters differed in malignancy response 142
Sphere formation efficiency was measured as an in vitro means to assess tumor initiation 143 potential in a random subsample of five gliomasphere lines from each cluster which included 144 proneural, classical and mesenchymal samples. (Fig. 3C) . Non-parametric Mann-Whitney U 145 tests of sphere formation efficiency showed significantly higher sphere formation efficiency in 146 AKTAKT/TORC1 activated Cluster II in comparison to EGFR expressing Cluster I (p = .0159, 147 SD = 139.04). Though statistically significant, the standard deviation was quite large for definitive 148 discrimination between clusters. 149
Kaplan-Meier curves were generated based on progression free survival and overall 150 survival of patients gliomasphere lines were derived from ( Supplementary Figure 4b) . Though 151 there were trends of better prognosis in EGFR expressing Cluster I and poorer prognosis in 152 AKT/TORC1 activated Cluster II, hazard ratios for these outcome measures were not statistically 153 significant in predicting prognosis. 154
155
Discussion 156 157
Single cell analysis for the purposes of cellularly heterogeneity profiling is becoming 158 increasingly relevant for diagnostics, drug discovery, preclinical drug development, and basic and 159 The clusters consisted of proneural, classical and mesenchymal TCGA groupings. All 204 EGFR expressing Cluster I proneural gliomaspheres had mutations in the isodehyrodgenase 205 isocitrate dehydrogenase (IDH1) gene, while all AKT/TORC1 activated Cluster II proneural 206 gliomaspheres did not harbor this mutation. Given IDH1 mutations are a feature of lower grade 207 brain tumors, consistent with the sphere forming ability of these samples. Additionally, through 208 recent evidence from other single cell analytical techniques, IDH1 mutation has been observed as 209 a feature of EGFR amplification, suggesting this clustering is reasonable. (30) 210 It is relevant to recognize bulk, uniparameter or quantitatively insensitive cell metrics could 211 have obscured subtle yet crucial, informative molecular differences in the cells which 212 multiparameter single cell clustered datasets resolve. Correlative analysis of individual proteins, 213 while identifying potentially meaningful correlations, could not reveal the level of cellular 214 complexity this type of multiparameter, parallel analyses was able to discern in terms of the 215 phenotypes identified. Of note, while some parameters studied did not reach statistical 216 significance, they were still vital to resolving phenotype clusters. The activated states of AKT and 217 TORC1, while of only borderline statistical significance, proved essential to distinguishing clusters. 218 This is an important consideration given dual inhibition of these targets has shown evidence of 219 therapeutic potential. This additionally supports an emerging understanding of low TORC1 220 activation is a defining and essential characteristic of gliomasphere and cancer stem cell phenotype 221 maintenance. (31) (27) 222 This study was limited by a modest number of samples analyzed. Parallel analysis is a 223 powerful approach to single cell heterogeneity analysis capacities, and 15 samples tested the 224 minimal number of samples needed to quantify these valuable cells for definitive global 225 understanding of this cell subtype. Sample number may have reduced statistical significance of the 226 markers tested and suggested trends, but did not achieve statistically significant prognostic 227 indication, latter particularly a measure to definitively prove these pathways as essential 228 malignancy drivers of these cells (Supplementary Information). (6) (32) PTEN was statistically 229 insignificant in gliomasphere lines and thus proteomic mapping capacities relied on only three 230 markers tested. Despite these limitations, this study did indeed provide insight into the clear utility 231 of quantitative single cell heterogeneity profiling and parallel analysis of these specific pathways 232 contribute to and resolve molecular drivers of the cancer stem-like state and targeting of these cell 233 populations. 234
235
Materials and Methods 236 237
Microfluidic cell array chips 238
Each cell array chip consists of 24 (3 x 8) chambers, each with dimensions of 8 mm (l) x 1 239 mm (w) x 120 um (h) and total volume of 960 nL (Fig. 1B) . Single cell suspension, culture media, 240 and reagents were introduced and removed at chip ports by electronic, handheld semi-automated 241 pipettor at 6uL/second to protect cells from shear forces and enable flexible reagent and cell control. To prepare microfluidic chips for cell loading, matrigel at 1:20 (BD Biosciences, Inc.) was 258 used as a cell capture reagent and loaded into chambers for 12 hours at 8 o C then washed with PBS. 259 Although precise cell densities at time of loading were dependent on individual sample 260 gliomasphere growth characteristics, cells were dissociated using TrypLE (Invitrogen), spun down 261 at 1200 RPM for 1 min and pelleted, then resuspended at a density of 50 to 500 cells/μL for a 100-262 1000 µL aliquot containing single cells with media in a 1.5mL tube (Eppendorf, Inc.). The tubes 263 were triturated with Matrix pipettor and 2uL of cell suspension was loaded per matrigel pretreated 264 microfluidic chamber. Three chambers were loaded per gliomasphere sample. Chips were then 265 spun at 1000 RPM for 1 minute to assure all cells would fall into the same Z-plane for imaging. 266
Chips were then placed in a 10-cm Petri dish with 1 mL double-distilled water (for hydration) and 267 incubated in a 5% CO2, 37°C incubator for 10 minutes prior to on-chip quantitative 268 immunocytometry. 269
270
Gliomasphere models 271
Collection of patient tumor tissue for the derivation of gliomaspheres was approved by the 272 Institutional Review Board of UCLA. Briefly, tumors were washed, minced with a scalpel blade, 273 digested with TrypLE (Invitrogen) for 5 minutes and spun down at 1200 RPM for 5 minutes. 274
TrypLE was removed and tumor pieces were resuspended in chilled DMEM-F12 (Invitrogen), 275 dissociated with at least 2 glass pasteur pipets (Fisher Brand) fire polished to successively smaller 276 bores and put through a 70µm and 40um cell strainers (BD Biosciences). A Percol (GE Health 277 Sciences) protocol was employed to remove red blood cells. (6) 278 Cells were seeded at a density of 100,000 cells/mL in a stem cell growth and enrichment 279 medium consisting of DMEM/F12 medium supplemented with 1:50 B27 (Invitrogen), 20 ng/ml 280 bFGF (Peprotech), 50 ng/mL EGF (Peprotech), 1:100 penicillin/streptomycin (Invitrogen), 1:100 281 Glutamax (Invitrogen) and 5 ug/ml heparin (Sigma-Aldrich). Heparin, bFGF and EGF were 282 involves repeated presentation of the training data to the map. Each presented datapoint is assigned 313 to a most similar "winning" grid and the codebook vector of the winning grid is updated using a 314 weighted average, where the weight is the learning rate α. Three SOMs are trained for each data 315 set, and the resulting maps examined for qualitative consistency. Testing various SOM grid sizes 316 identified a 7 x 7 grid as smallest size to capture differences between gliomasphere samples. (Fig.  317   2D) . 318
Hierarchical clustering of Neighborhood Frequency Vectors (NFVs) of SOMs (Fig. 2E,  319 3A) with waterfall plots displaying differing average intensities values for each cluster were 320 generated (Fig. 2B, 2F) . Further analytical details can be found in the Supplemental Methods. Neurosphere size and number measurements were obtained with an Acumen eX3 plate 343 reader in the UCLA California NanoSystems Institute (CNSI) Molecular Shared Screening 344
Resource core facility. For this, cells were fixed with 1:1 mixture of 4% paraformaldehyde and 345 100% methanol, 50 µL/well. After at least 4 hrs post-fixation the DNA binding Syto-9 dye was 346 added (1:1000 dilution in PBS, 10 µL/well). The parameters from data output for each identified 347 object included peak and total intensities (FLU), diameter (expressed as width and depth in µm), 348 and spherical volume (µm3). Thresholds for false, i.e. non-neurosphere objects (e.g., cell clumps, 349 single cells, DNA remnants, debris, etc), were defined by: 1) objects with diameter <35 um, 2) 350 peak intensity <100 FLU or 3) width/depth ratio >4. After setting thresholds, means and standard 351 error for sphere numbers were calculated based on number of objects from an average of 10 wells 352 and mean spherical volume per condition to estimate neurosphere size. Limiting dilution assays were performed by single cell dissociation and resuspension in 366 neurosphere media and plated into 96 well microplates. A measure of sphere forming efficiency 367 was achieved by seeding incrementally increasing numbers of cells at intervals 50 cells up to 800 368 cells/well and assessing the number of cells required to achieve ten gliomasphere spheres per well. 369
Plates were incubated and monitored for sphere formation over a 16 day incubation period. The 370 minimal cell density to achieve 10 gliomasphere neurospheres per well is reported (Fig. 3C) 504  505  506  507  508  509  510  511  512  513  514  515  516  517 
